Patients with primary metastatic/recurrent endometrial cancer have poor prognosis and available therapeutic options are limited. Current treatment is mainly based on platinum-based chemotherapy. Recently, the Food and Drug Administration (FDA) granted approval for the combination of pembrolizumab and lenvatinib for endo-metrial cancer patients without microsatellite instability (MSS) progressing on a previous line of therapy while European Medicines Agency (EMA) approved the combination for all comers patients failing previous platinum treatment. Anti programmed cell death protein-1 (PD-1) dostarlimab (TSR-042) was approved as monotherapy in patients with advanced, microsatellite instable (MSI) endometrial cancer progressing to platinum treatment. Phase II-III clinical trials in metastatic endometrial cancer are mainly focused on target therapies and immu-notherapy as single agents or in combination. Unfortunately, most of these trials are lacking of predictive bio-markers of response to select patients most or at least likely to benefit from those treatments.
Advanced and recurrent endometrial cancer: State of the art and future perspectives / Tronconi, Francesca; Nero, Camilla; Giudice, Elena; Salutari, Vanda; Musacchio, Lucia; Ricci, Caterina; Carbone, Maria Vittoria; Ghizzoni, Viola; Perri, Maria Teresa; Camarda, Floriana; Gentile, Marica; Berardi, Rossana; Scambia, Giovanni; Lorusso, Domenica. - In: CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY. - ISSN 1040-8428. - 180:(2022), p. 103851. [10.1016/j.critrevonc.2022.103851]
Advanced and recurrent endometrial cancer: State of the art and future perspectives
Berardi, Rossana;
2022-01-01
Abstract
Patients with primary metastatic/recurrent endometrial cancer have poor prognosis and available therapeutic options are limited. Current treatment is mainly based on platinum-based chemotherapy. Recently, the Food and Drug Administration (FDA) granted approval for the combination of pembrolizumab and lenvatinib for endo-metrial cancer patients without microsatellite instability (MSS) progressing on a previous line of therapy while European Medicines Agency (EMA) approved the combination for all comers patients failing previous platinum treatment. Anti programmed cell death protein-1 (PD-1) dostarlimab (TSR-042) was approved as monotherapy in patients with advanced, microsatellite instable (MSI) endometrial cancer progressing to platinum treatment. Phase II-III clinical trials in metastatic endometrial cancer are mainly focused on target therapies and immu-notherapy as single agents or in combination. Unfortunately, most of these trials are lacking of predictive bio-markers of response to select patients most or at least likely to benefit from those treatments.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
